Table 3.
Univariate survival model
| Clinicopathologic variable | COH/UCD (n = 341) | MSKCC (n = 934) | ||
|---|---|---|---|---|
| HR (95%CI) | p value | HR (95%CI) | p value | |
| Age at diagnosis, continuous, yr | 1.00 (0.98–1.01) | .553 | 1.01 (1.00–1.02) | .294 |
| Gender, female vs. male | 1.00 (0.76–1.32) | .986 | 0.96 (0.78–1.19) | .713 |
| Primary tumor location, right vs. left | 1.61 (1.20–2.16) | .0017 | 1.64 (1.30–2.07) | 3.66 × 10−05 |
| APC, mutated vs. nonmutated | 0.54 (0.40–0.73) | 5.95 × 10−05 | 0.55 (0.44–0.70) | 8.36 × 10−07 |
| KRAS, mutated vs. nonmutated | 1.11 (0.85–1.46) | .447 | 1.37 (1.10–1.70) | .0044 |
| NRAS, mutated vs. nonmutated | 1.20 (0.59–2.45) | .622 | 1.75 (0.11–2.76) | .0153 |
| BRAF, mutated vs. nonmutated | 2.00 (1.30–3.08) | .0016 | 3.10 (2.27–4.24) | 9.67 × 10−13 |
| BRAF V600E, mutated vs. nonmutated | 2.56 (1.50–4.35) | 5.47 × 10−04 | 4.61 (3.22–6.61) | 8.17 × 10−17 |
| TP53, mutated vs. nonmutated | 1.33 (0.93–1.88) | .114 | 1.00 (0.77–1.30) | .989 |
| ARID1A, mutated vs. nonmutated | 1.11 (0.56–2.17) | .769 | 1.03 (0.56–1.87) | .934 |
| CTNNB1, mutated vs. nonmutated | 0.95 (0.35–2.55) | .913 | 1.67 (0.86–3.26) | .133 |
| FBXW7, mutated vs. nonmutated | 0.48 (0.25–0.91) | .025 | 1.20 (0.79–1.84) | .394 |
| RNF43, mutated vs. nonmutated | 4.18 (1.84–9.48) | 6.38 × 10−04 | 3.75 (2.23–6.32) | 6.8 × 10−07 |
| SOX9, mutated vs. nonmutated | 0.51 (0.28–0.93) | .029 | 0.75 (0.49–1.15) | .187 |
Abbreviations: CI, confidence interval; COH, City of Hope National Medical Center; HR, hazard ratio; MSKCC, Memorial Sloan Kettering Cancer Center, UCD, University of California, Davis.